Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026
Key Highlights
- ➤November 20 presentation will feature updated pivotal Phase 2 PYNNACLE results
- ➤PYNNACLE Phase 2 is a registrational, single-arm trial spanning five cancer cohorts
- ➤Trial evaluates rezatapopt in TP53 Y220C-positive advanced solid tumors
- ➤Trial is being conducted across approximately 70 sites
- ➤FDA granted rezatapopt Fast Track and Orphan Drug designations
Expert Statements
Alison M. Schram, M.D., Memorial Sloan Kettering Cancer Center
“Efficacy, molecular activity and safety from the pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a p53 reactivator, in TP53 Y220C-positive advanced solid tumors”
PRINCETON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced that updated results from the pivotal Phase 2 portion of the PYNNACLE clinical trial of rezatapopt will be featured in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) (link). The presentation will include updated data from all PYNNACLE trial cohorts.
Title: Efficacy, molecular activity and safety from the pivotal PYNNACLE Phase 2 trial assessing rezatapopt, a p53 reactivator, in TP53 Y220C-positive advanced solid tumors
Get started
Create a free account to read the full story.